Contact Us
Company Overview
|
Pipeline / Clinical Trials
|
Science & Discovery
|
Business Development
|
Investors
Overview
|
Stock Data
|
Governance
|
SEC Filings
|
News & Events
|
Presentations
|
Fundamentals
|
Information Request
Press Release Archive
Press Release Archive
2010
>
2009
>
2008
>
2007
>
2006
>
2005
> 2004 >
2003
>
2002
>
2001
December 20, 2004
RegeneRx Files with FDA for Second Phase II Clinical Trial
November 24, 2004
Researchers Report Wound Healing Drug Significantly Reduces Cardiac Damage After Heart Attack
November 2, 2004
RegeneRx Cleared to Initiate Phase II Clinical Trial with Tß4 for Chronic Pressure Ulcers
September 8, 2004
RegeneRx Receives $1.5 Million From Exercise of Warrants
August 17, 2004
Scientists Show Tß4 Can be Chemically Integrated Into Fibrin
June 24, 2004
RegeneRx Holds 2004 Annual Stockholders' Meeting
June 23, 2004
Sigma-Tau to Conduct Phase II Clinical Trial in Europe with Tß4 for Venous Stasis Ulcers
June 10, 2004
RegeneRx Adds Dr. Paolo Carminati to Medical and Scientific Advisory Board
June 4, 2004
RegeneRx Receives Orphan Drug Designation for Thymosin Beta 4 for the Treatment of Epidermolysis Bullosa
April 26, 2004
Tß4 Significantly Reduced In Old Animals After Corneal Injury
April 26, 2004
Tß4 Decreases Inflammation & Bleeding in Eye After Injury
April 20, 2004
RegeneRx Adds Two Members to Medical and Scientific Advisory Board
April 1, 2004
RegeneRx Reports 2003 Year-End Results
March 29, 2004
Two Abstracts on Tß4 and Ocular Wound Healing Selected for Presentation at ARVO Annual Meeting
March 24, 2004
RegeneRx's Tß4 Reported to Inhibit Human Corneal Apoptosis (Cell Death)
March 18, 2004
RegeneRx's Drug Subject of First Issued Patent for Wound Healing
February 2, 2004
RegeneRx's Tß4 Stimulates Critical Wound Healing Protein
January 23, 2004
RegeneRx Completes $2.3 Million Private Placement
January 22, 2004
RegeneRx Licenses European Rights to Novel Wound Healing Drug
home
|
Contact Us
|
Resources
|
Site Map
|
Search
